Search

Displaying results 1481 - 1490 of 10000 in total
  1. Drug

    Bupropion

    go.drugbank.com/drugs/DB01156
    ApprovedInvestigational

    [L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo … Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective

    Mixtures: Appbutamone-DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  2. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects.

    Synonyms: Lanthanum(3+) carbonateProducts: FOSRENOL 500 MG, Fosrenol 500 mg Kautabletten
  3. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: SPASMEX 30 MG FILM TABLET, 100 ADET, TROSBIO® 30 MG
  4. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525] … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.

    Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsProducts: Zeldox 10 mg/ml Suspension zum Einnehmen, GEODON® CAPSULAS 80 MG
  5. Drug

    Fenvalerate

    go.drugbank.com/drugs/DB18391
    Experimental

    Synonyms: methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3- ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate, -cyano-3-phenoxybenzyl (2rs)-2-(4-chlorophenyl)-3-methylbutyrateCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B … It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: KELAC® 20 MG, BRINTELLIX® 10 MG
  7. Drug

    Fluticasone furoate

    go.drugbank.com/drugs/DB08906
    ApprovedInvestigational

    Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].

    Mixtures: RELVAR ELLIPTA 100/25 MCG KULLANIMA HAZIR INHALASYON TOZU ,3 X 30, TRELEGY ELLIPTA INHALATION POWDER 100 MCG/62.5 MCG/25 MCGCategories: P-glycoprotein inducers, P-glycoprotein substrates
  8. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    a treatment for COVID-19. … Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVİ 10 MG TABLET, 168 ADET, JAKAVİ 10 MG TABLET, 56 ADET
  9. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADET
  10. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    influenza is a self-limiting illness. … Notably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness.

    Synonyms: Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-Products: TAMIFLU® CAPSULAS 75 MG, TAZAMIR(R) CAPSULA 75 MG